ArticleCommunications medicine2025
Unveiling proteomic and peptide-level modifications in cerebrospinal fluid and plasma in normal cognitive aging.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Aptamer-Based Platforms for Human Aging Biomarkers: Multiplexed Proteomics, Biosensors and Translational Perspectives.International journal of molecular sciences · 2026Review
- Cross-disease LC-MS/MS plasma proteomics identifies reproducible shared and disease-enriched biomarker signatures in neurodegenerative disorders.Acta neuropathologica communications · 2026Article
- Proteomics of aging: biomarkers for physiological systems and diseases.Frontiers in aging · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundNormal cognitive aging is accompanied by molecular changes in the brain and periphery, but the specific proteomic and peptide-level alterations remain poorly defined. This study aimed to characterize age-related protein and peptide modifications by analyzing matched cerebrospinal fluid (CSF) and plasma samples from cognitively normal individuals.
methodsMass spectrometry was used to profile the proteome and peptide-level data of CSF and plasma samples from young (n = 52; mean age 29 ± 5.9 years; 4% male) and older (n = 40; mean age 69 ± 6.3 years; 48% male) adults. Differential abundance analysis, gene set enrichment, and weighted correlation network analyses were performed to identify age-associated pathways. Protein cleavage, alternative splicing, and phosphorylation events were examined to capture post-translational modifications linked to aging.
resultsIn CSF, aging is associated with significant upregulation of extracellular matrix (ECM) components, coagulation, and inflammatory pathways. In plasma, the insulin-like growth factor-1 (IGF-1) signaling pathway is notably downregulated. Peptide-level analysis reveals novel alternative cleavage and phosphorylation patterns in key proteins involved in lipid metabolism, ECM structure, axonogenesis, and synaptic activity, including APP, APOE, COL4A2, NRXN1, and NRCAM. These findings highlight distinct and compartment-specific molecular changes that occur with aging.
conclusionsThis study provides a comprehensive proteomic and peptide-level landscape of normal cognitive aging, identifying both protein-level shifts and novel age-associated cleavage and phosphorylation events.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.